This table lists all the major pharma collaborations, acquisitions and mergers agreed during September 2014.
For an indepth analysis of these deals, read ‘Pharma deals during September 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Sigma Aldrich / Merck KGaA | Company acquisition | Laboratory supplies | 17,000 |
| Alios / J&J | Company acquisition | Anti-viral therapies, lead compound AL-8176 an oral antiviral in phase II for infant RSV | 1,750 |
| Lumara Health / Amag
Lumara Health / Perrigo |
Company acquisition (excluding Perrigo products) | Maternal health business including orphan drug to reduce risk of preterm birth Makena
Three women’s health products |
1,025
82 |
| Merrimack / Baxter | Licence to commercialise1 | MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III | 970 |
| Infinity / AbbVie | Licence and collaboration | IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia | 805 |
| Curevac / Boehringer Ingelheim | Licence and collaboration | Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer | 601 |
| Civitas / Acorda | Company acquisition | CVT-301 – Levodopa dry powder inhaler. Phase IIb for treatment of Parkinsons + pulmonary delivery technology | 525 |
| AstraZeneca / Lilly | Licence and collaboration | Oral BACE inhibitor in phase I for Alzheimer’s disease | 500 |
| Ambit Biosciences / Daiichi Sankyo | Company acquisition | Kinase inhibitor pipeline, lead compound quizartinib for AML in phase III | 410 |
| Aesica Pharmaceutical / Consort | Company acquisition | Aesica is a UK contract development and manufacturing company | 374 |
| Aspen / Mylan | Product acquisition2 | Arixtra anticoagulant plus authorised generic version | 300 |
| Sutro / Merck KGaA | Licence and collaboration | Sutro’s antibody drug conjugate technology for oncology | 298 |
| Rhizen / TG Therapeutics | Licence and collaboration3 (exercise of option) | TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies | 244 |
| Seattle Genetics / Genmab | Licence and collaboration | Additional deal to use Seattle’s antibody drug conjugate technology | 211 |
| Altor / Shenzhen Beike | Licence and collaboration4 | ALT-803 an interleukin-15-based agonist in Phase I/II for treatment of various cancers | 209 |
| MyoKardia/ Sanofi | Licence and collaboration5 | Three programmes for treatment of genetic forms of cardiomyopathy | 200 |
| Shasun / Strides Arcolab | Company acquisition | Shasun is an Indian API and generic company | 200 |
| Innovus / Sothema Labs
Innovus / Orimed |
Licence to commercialise6
Licence to commercialise7 |
Natural oils to treat female sexual desire disorder (Zestra) and various penile disorders (EjectDelay, Sensum) | 171
86 |
| Isopure / Glanbia | Company acquisition | Glanbia, US company selling premium branded sports nutrition powders and drinks | 153 |
| NeuroVive / OnCore | Licence and collaboration | NVP018 an oral sangamide-based 2nd generation cyclophilin inhibitor for hepatitis B | 150 |
All deals are worldwide unless otherwise noted
1: Global excluding US and Taiwan
2: US only
3: Excludes India
4: China only
5: Excluding commercialisation in US
6: Middle East and Africa
7: Canada